Cinetto et al. reported that the levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 were increased in the BALF of BLM-treated mice and that glycogen synthase 3 (GSK-3) inhibition may modulate MMP-2, MMP-9, TIMP-1, and TIMP-2 activity in BALF and lung tissue, thus preventing BLM-induced lung injury [93]. The gene discussed is TIMP2; the disease is Bloom syndrome.